coronavirus
Additional manufacturing capacity for BioNTech/Pfizer’s COVID-19 vaccine
EMA has recommended the approval of additional manufacturing and filling lines at Pfizer’s vaccine manufacturing site in Puurs, Belgium. The recommendation by the Agency’s Committee for Human Medicines (CHMP) is expected to have a significant and immediate impact on the supply of Comirnaty, the COVID-19 vaccine developed by BioNTech and Pfizer, in the European Union.
Based on the review of the data submitted by BioNTech Manufacturing GmbH, EMA’s decision reaffirms that the Puurs facility is capable of consistently producing high-quality vaccines and enables Pfizer/BioNTech to increase the volumes of vaccines produced at this site.
The changes described will be included in the publicly available information on this vaccine on EMA’s website.
Related content
Related content
- Coronavirus disease (COVID-19)
- COVID-19: latest updates
- COVID-19 vaccines: authorized
- COVID-19 vaccines: development, evaluation, approval and monitoring
- Committee for Medicinal Products for Human Use (CHMP)
Share this article:
EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter. Please see EU Reporter’s full Terms and Conditions of publication for more information EU Reporter embraces artificial intelligence as a tool to enhance journalistic quality, efficiency, and accessibility, while maintaining strict human editorial oversight, ethical standards, and transparency in all AI-assisted content. Please see EU Reporter’s full A.I. Policy for more information.
-
Sport3 days agoWho will win the 2026 World Cup? Data points to Spain
-
Russia5 days agoWestern investors eye Russian assets again as sanctions discounts persist
-
Green Week5 days agoEU green jobs: Which activities employ the most people?
-
EU5 days agoGovernment gross debt of eurozone largely in euro
